secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001641172-25-024303
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Three directors resign after D&O insurance lapse; $550K convertible note issued
-------------------------------------------------------------------------------

- Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
- D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.
- Entered agreement with Lambda Venture Partners for up to $550K principal, $500K funding; first tranche $110K/$100K.
- Notes bear 8% interest, one-year term, convertible at 35% discount to lowest traded price in prior 10 days.
- No warrants issued; securities sold under Section 4(a)(2) exemption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000164117225024303/0001641172-25-024303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000164117225024303/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer